CRT前后血清MMP-2、9和NT-pro-BNP水平及意义  

The levels and meaning of serum N-terminal pro-brain natriuretic peptide and matrix metalloproteinase-2,9 in preoperative and postoperative cardiac resynchronization therapy

作　　者：李镇[1,2] 徐健[1] 苏浩[1] 程久佩 邵名亮[2] 方存明 

机构地区：[1]安徽医科大学附属省立医院心血管内科,合肥230001 [2]安徽省宣城市人民医院心血管内科,宣城242000

出　　处：《安徽医科大学学报》2012年第9期1134-1136,共3页Acta Universitatis Medicinalis Anhui

摘　　要：回顾性分析我院行心脏再同步化治疗(CRT)前后心力衰竭患者血清N端脑钠肽(NT-pro-BNP)、基质金属蛋白酶2、9(MMP-2、9)水平变化对评价CRT疗效的可行性。采用酶联免疫法(ELISA)检测血清MMP-2、9和NT-pro-BNP水平。结果表明,CRT组术后3、6个月血清MMP-2、9和NT-pro-BNP水平显著低于术前及对照组(P<0.05)。血清MMP-2、9和NT-pro-BNP可以作为评价CRT疗效的生化指标。To analyse the feasibility that serum NT-pro-BNP and matrix metalloproteinase -2,9 concentration changes to curative effect evaluation preoperative and postoperative cardiac resynchronization therapy. Serum NT-pro- BNP, MMP- 2,9 were detected with ELISA. This results showed that the third and sixth months after CRT, serum NT-pro-BNP, MMP-2,9 were significantly lower than those of the preoperative and control group （ P 〈 0.05 ）. Therefore, serum NT-pro-BNP, MMP-2,9 can serve as indicators to evaluate the effectiveness of CRT.

关 键 词：心脏再同步化治疗 N端脑钠肽 基质金属蛋白酶2、 9 

分 类 号：R541.61[医药卫生—心血管疾病]